The six indicators with the highest reported frequency in safety evaluation for hyperlipidemia patients were as follows: total adverse events, adverse drug-related events, elevated ALT/aspartate aminotransferase level, elevated blood creatine phosphokinase level, myalgia, and gastrointestinal disorders. Here, GPT is linked to hyperlipidemia.